TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34978862

Group type: EXPERIMENTAL
Intervention: Observational population
Number of subjects: 137933

Group type: COMPARATOR
Intervention: Randomized population
Number of subjects: 137933

Group type: EXPERIMENTAL
Intervention: Risk adjustment
Number of subjects: 137933

Group type: EXPERIMENTAL
Intervention: Further adjustment for social factors
Number of subjects: 137933
Study: 33477108

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) (3 × 3 min at 10°C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Static stretching (SS) (9 × 30‐s carpal extension)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study: 34951029

Group type: EXPERIMENTAL
Intervention: Positive diary intervention (writing down three good things each day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (keeping a record of each meal for 4 weeks)
Number of subjects: 0
Study: 32370640

Group type: EXPERIMENTAL
Intervention: Propensity score-integrated composite likelihood approach (PSCL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-world data (RWD) patients treated with the same therapy as the control arm
Number of subjects: 0
Study: 34560687

Group type: EXPERIMENTAL
Intervention: Dynamic mechanical power calculated using the power equation adjusted by the respiratory system compliance (CRS)
Number of subjects: 1156
Study: 32107315

Group type: EXPERIMENTAL
Intervention: Modified complex decongestive physiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (health education program)
Number of subjects: 120
Study: 34176749

Group type: EXPERIMENTAL
Intervention: Sacral transcutaneous electrical nerve stimulation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 86
Study: 33487192

Group type: EXPERIMENTAL
Intervention: 1 per cent diluted vinegar
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 per cent chloramphenicol
Number of subjects: 24
Study: 33121883

Group type: EXPERIMENTAL
Intervention: Random forest model
Number of subjects: 20716

Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 20716

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 20716

Group type: COMPARATOR
Intervention: Machine learning models (random forest, XGBoost, logistic regression)
Number of subjects: 20716
Study: 35861265

Group type: EXPERIMENTAL
Intervention: EAB modification (EABM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 90
Study: 33731270

Group type: EXPERIMENTAL
Intervention: Oral lefamulin 600 mg every 12 h for 5 days
Number of subjects: 368

Group type: COMPARATOR
Intervention: Oral moxifloxacin 400 mg every 24 h for 7 days
Number of subjects: 368
Study: 33171645

Group type: EXPERIMENTAL
Intervention: NNS consumption (aspartame)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NNS consumption (total NNS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Weight and BMI changes
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Diet soda consumption
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sucralose and saccharin intake
Number of subjects: 101
Study: 35362417

Group type: EXPERIMENTAL
Intervention: Standard cancer care plus early integrated palliative care
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard cancer care
Number of subjects: 98
Study: 34512011

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 62

Group type: COMPARATOR
Intervention: General anesthesia and multi-modal analgesia (Control Group G)
Number of subjects: 62
Study: 34352596

Group type: EXPERIMENTAL
Intervention: Auricular acupressure on sleep-disorder-related points
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham control (auricular acupressure on sleep-disorder-unrelated points)
Number of subjects: 42
Study: 33143507

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluorapatite (FA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Uncoated Mallory‐Head Porous stem
Number of subjects: 53
Study: 33884659

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 62

Group type: COMPARATOR
Intervention: GnRHa buserelin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Uterine oedema and full acceptance of the teaser stallion
Number of subjects: 62
Study: 34190182

Group type: EXPERIMENTAL
Intervention: Home-reablement program for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional rehabilitation in the hospital
Number of subjects: 26
Study: 35941932

Group type: EXPERIMENTAL
Intervention: anodal tDCS (atDCS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: bilateral tDCS (bi-tDCS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: cathodal tDCS (ctDCS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 32
Study: 33655587

Group type: EXPERIMENTAL
Intervention: Common cold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nine acute upper RTIs (9-AURTIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall RTIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socio-demographic, behavioral, and environmental factors
Number of subjects: 0
Study: 32217500

Group type: EXPERIMENTAL
Intervention: Mobile Interactive Supervised Therapy (MIST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study: 34561939

Group type: EXPERIMENTAL
Intervention: Dialysis Dementia Risk Score (DDRS)
Number of subjects: 32288

Group type: EXPERIMENTAL
Intervention: Validation of DDRS
Number of subjects: 32288
Study: 34291484

Group type: EXPERIMENTAL
Intervention: LVA guided ablation in addition to pulmonary vein isolation (PVI)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: LVA guided ablation in addition to PVI
Number of subjects: 340
Study: 32809152

Group type: EXPERIMENTAL
Intervention: Initial medical management (medical treatment based on anticoagulation, delayed by 24 hours if intravenous thrombolysis was performed)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Initial medical management
Number of subjects: 56
Study: 35306197

Group type: EXPERIMENTAL
Intervention: DBS model plus standard patient education (PE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard patient education (PE) alone
Number of subjects: 40
Study: 34213495

Group type: EXPERIMENTAL
Intervention: Hydrogen-dissolved alkaline electrolyzed water (AEW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purified tap water
Number of subjects: 0
Study: 32997816

Group type: EXPERIMENTAL
Intervention: Double blade scalpel (DBS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: De‐epithelialized (DE) SCTG
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both techniques (DBS and DE)
Number of subjects: 21
Study: 36111547

Group type: EXPERIMENTAL
Intervention: Adherence Club (AC) - community health worker-led groups of 20-30 patients with ART dispensing at a community venue
Number of subjects: 409

Group type: COMPARATOR
Intervention: Routine PHC clinics - local standard of care with nurse/doctor-led services
Number of subjects: 409
Study: 32603526

Group type: EXPERIMENTAL
Intervention: Roxadustat (1 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Roxadustat (2 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 34351401

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 136

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 136
Study: 32424821

Group type: EXPERIMENTAL
Intervention: Very Integrated Program (VIP) - a 6-week intensive, tailored, educational program including motivational interviewing, smoking cessation program, dietary and physical activity counseling, and patient education.
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (addiction care as usual)
Number of subjects: 212
Study: 34032530

Group type: EXPERIMENTAL
Intervention: USRPT
Number of subjects: 14

Group type: COMPARATOR
Intervention: RPT
Number of subjects: 14
Study: 33545710

Group type: EXPERIMENTAL
Intervention: Outcome-optimized radiotherapy (OORT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dose-optimized radiotherapy (DORT)
Number of subjects: 10
Study: 33471202

Group type: EXPERIMENTAL
Intervention: Tecnis ZLB00 IOL
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diffractiva IOL
Number of subjects: 35
Study: 33049927

Group type: EXPERIMENTAL
Intervention: Ergonomics educational program
Number of subjects: 74
Study: 35913014

Group type: EXPERIMENTAL
Intervention: Forward‐back Spanish translation
Number of subjects: 380

Group type: COMPARATOR
Intervention: Rigorous translation with cultural adaptation
Number of subjects: 380
Study: 32941265

Group type: EXPERIMENTAL
Intervention: Treatment for ruptured AVMs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of unruptured AVMs
Number of subjects: 0

Group type: COMPARATOR
Intervention: ARUBA trial
Number of subjects: 0
Study: 34906127

Group type: EXPERIMENTAL
Intervention: The Real Cost Smokeless campaign
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Overall sample (including treatment and control)
Number of subjects: 2200
Study: 32509046

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided inactivation of myofascial trigger points (MTrPs) with dry needling, followed by wet needling and muscle fascia stripping by liquid knife in PL group.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided inactivation of MTrPs with dry needling, followed by wet needling and muscle fascia stripping by liquid knife in PA group.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Routine oral drugs and weekly paraspinal nerve block in C1 group.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Routine oral drugs and weekly paraspinal nerve block in C2 group.
Number of subjects: 132
Study: 34542001

Group type: EXPERIMENTAL
Intervention: Multi‐layer rack group (MULTI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One‐touch pole clamp group (ONE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study: 33518062

Group type: EXPERIMENTAL
Intervention: Berberine (BBR) 250 mg/kg
Number of subjects: 360

Group type: COMPARATOR
Intervention: Antibiotic positive control (200 mg/kg oxytetracycline calcium and 250 mg/kg nasiheptide)
Number of subjects: 360
Study: 32496526

Group type: EXPERIMENTAL
Intervention: Original prediction model for POAG development (C statistic = 0.741)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Maximum IOP
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: SD of IOP
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Range of IOP
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Coefficient of variation IOP
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Prediction model including mean follow-up IOP, age, central corneal thickness, vertical cup-disc ratio, and pattern SD
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Placebo group from EGPS
Number of subjects: 1106
Study: 32732773

Group type: EXPERIMENTAL
Intervention: Blood flow restriction therapy on one arm
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham therapy on the other arm
Number of subjects: 19
Study: 33858976

Group type: COMPARATOR
Intervention: Denosumab Q3M (P/Q3M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Denosumab Q6M (P/Q6M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denosumab Q3M (Q3M/Q3M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denosumab Q6M (Q6M/Q6M)
Number of subjects: 0
Study: 35640922

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 2204
Study: 34443991

Group type: EXPERIMENTAL
Intervention: LOVED program (n = 24)
Number of subjects: 24
Study: 32589648

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg bid for eight weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard doses of rifampicin, isoniazid, pyrazinamide and ethambutol
Number of subjects: 39
Study: 35599420

Group type: EXPERIMENTAL
Intervention: Combined training group (bicycle ergometer rehabilitation training + conventional rehabilitation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined training group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional training group
Number of subjects: 40
Study: 33774144

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gross Motor Abilities (GMA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cognitive Training (COG)
Number of subjects: 78
Study: 33302662

Group type: EXPERIMENTAL
Intervention: Indomethacin + nitroglycerin
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526

Group type: COMPARATOR
Intervention: PSP
Number of subjects: 526
Study: 34984822

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitor (empagliflozin)
Number of subjects: 48
Study: 33492703

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 32965602

Group type: EXPERIMENTAL
Intervention: Biosimilar ABP 798
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab reference product
Number of subjects: 0
Study: 35232894

Group type: EXPERIMENTAL
Intervention: DA-9701 (30 mg, 3 times a day for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32321478

Group type: EXPERIMENTAL
Intervention: Strong-fear-plus-empowerment message
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Mild-fear-plus-empowerment message
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Fear-alone message
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: All messages (not 'very/somewhat new')
Number of subjects: 4000
Study: 35101346

Group type: EXPERIMENTAL
Intervention: Cetuximab plus avelumab (rechallenge therapy)
Number of subjects: 77
Study: 33650779

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.3–0.9 mg/day)
Number of subjects: 40
Study: 35658800

Group type: EXPERIMENTAL
Intervention: LOW (1 hour/week)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MOD (2 hours/week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 52
Study: 34419277

Group type: COMPARATOR
Intervention: Control group (milk replacer only)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Milk replacer mixed with antirotavirus antibodies
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Colostrum replacer mixed with antirotavirus antibodies
Number of subjects: 83
Study: 33714487

Group type: EXPERIMENTAL
Intervention: Myofascial release maneuver (MLM) applied to lower limb muscle chains
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 63
Study: 36001544

Group type: EXPERIMENTAL
Intervention: Visual clinical examination using ICDAS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: iTero Element 5D System (intraoral scanner with near infrared imaging technology)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bitewing radiography (BWX)
Number of subjects: 80
Study: 34189603

Group type: EXPERIMENTAL
Intervention: Caffeinated diet cola (CAF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cola containing caffeine and carbohydrates (CAF+CHO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Flattened decaffeinated diet cola (PLA)
Number of subjects: 13
Study: 35387611

Group type: EXPERIMENTAL
Intervention: Integrated Vector Management (IVM) combining targeted outdoor residual spraying (TORS), deployment of auto-dissemination devices (ADDs), and active community engagement (CE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted outdoor residual spraying (TORS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deployment of auto-dissemination devices (ADDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active community engagement (CE)
Number of subjects: 0
Study: 34346165

Group type: COMPARATOR
Intervention: Single intravenous dose of NL005 (0.05, 0.25, 0.5, 2.0, 5.0, 12.5 or 25.0 μg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Multiple intravenous doses of NL005 (0.5, 2.0 and 5.0 μg/kg) administered once daily for 10 days
Number of subjects: 54
Study: 32989366

Group type: EXPERIMENTAL
Intervention: Physician recommendation for HPV vaccination
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Various factors associated with HPV vaccine hesitancy
Number of subjects: 317
Study: 32586143

Group type: EXPERIMENTAL
Intervention: On-treatment HDL in the lowest quartile (≤ 1.21 mmol/l)
Number of subjects: 8267

Group type: EXPERIMENTAL
Intervention: On-treatment HDL in the second and third quartiles
Number of subjects: 8267

Group type: EXPERIMENTAL
Intervention: Baseline HDL in the lowest quartile (≤ 1.21 mmol/l)
Number of subjects: 8267

Group type: EXPERIMENTAL
Intervention: On-treatment HDL in the lowest quartile
Number of subjects: 8267

Group type: EXPERIMENTAL
Intervention: Baseline HDL ≤ 1.21 mmol/l
Number of subjects: 8267
Study: 36040917

Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe with clopidogrel or ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe with ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin with ticagrelor
Number of subjects: 0
Study: 33420951

Group type: EXPERIMENTAL
Intervention: Sorafenib (Arm A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pravastatin (Arm B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sorafenib-Pravastatin combination (Arm C)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Best supportive care (Arm D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sorafenib (not treated with sorafenib)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Not treated with sorafenib
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sorafenib (in ALBI grade 1/2)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Not treated with sorafenib (in ALBI grade 1/2)
Number of subjects: 160
Study: 34847564

Group type: EXPERIMENTAL
Intervention: Exercise group (group-exercise training once weekly and independent exercises at home twice weekly for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (general care)
Number of subjects: 60
Study: 35355441

Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 645

Group type: COMPARATOR
Intervention: HFrEF patients
Number of subjects: 645
Study: 33631112

Group type: EXPERIMENTAL
Intervention: Ublituximab plus ibrutinib
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ibrutinib alone
Number of subjects: 126
Study: 36162037

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks
Number of subjects: 1833

Group type: COMPARATOR
Intervention: Nivolumab 480 mg once every 4 weeks
Number of subjects: 1833
Study: 34441023

Group type: EXPERIMENTAL
Intervention: New classification of diabetic foot syndrome adapted for ICD-10
Number of subjects: 492
Study: 32461038

Group type: COMPARATOR
Intervention: No psychotropic drugs
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: ≥3 psychotropic drugs
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Use of antidepressant agents in mild and moderate dementia
Number of subjects: 431
Study: 91215444

Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Stapling
Number of subjects: 1004
Study: 35995102

Group type: EXPERIMENTAL
Intervention: Usual-brand cigarettes
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Study cigarettes (0.4, 2.4, 15.8 mg/g)
Number of subjects: 775

Group type: COMPARATOR
Intervention: 0.4 mg/g nicotine content
Number of subjects: 775
Study: 34283906

Group type: EXPERIMENTAL
Intervention: Weekly educational SMS for 6 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: No SMS at all (control group)
Number of subjects: 128
Study: 35809280

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral block before induction of ropivacaine+butorphanol anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine operation anesthesia
Number of subjects: 100
Study: 32466811

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment plus treatment as usual (MBTp + TAU)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 84
Study: 32284053

Group type: EXPERIMENTAL
Intervention: 48 mg sucralose
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 96 mg sucralose
Number of subjects: 137

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 137
Study: 34498314

Group type: EXPERIMENTAL
Intervention: Infliximab plus thiopurines (combination therapy)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 620

Group type: COMPARATOR
Intervention: Overall cohort (combination therapy vs. monotherapy)
Number of subjects: 620

Group type: COMPARATOR
Intervention: MarketScan cohort
Number of subjects: 620

Group type: COMPARATOR
Intervention: Optum cohort
Number of subjects: 620

Group type: COMPARATOR
Intervention: SNDS cohort
Number of subjects: 620
Study: 32312265

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise + placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exercise + ICT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exercise + SDT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exercise + PHOTO
Number of subjects: 100
Study: 35945719

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy along with tennis ball myofascial release (6 sessions, 35 minutes/session for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional physiotherapy only (control group, n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy along with tennis ball myofascial release
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional physiotherapy only (control group)
Number of subjects: 22